Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Sep 20 03:46PM ET
4.52
Dollar change
+0.22
Percentage change
5.03
%
IndexRUT P/E- EPS (ttm)-0.51 Insider Own24.54% Shs Outstand63.77M Perf Week22.06%
Market Cap288.00M Forward P/E- EPS next Y-0.69 Insider Trans-13.36% Shs Float48.12M Perf Month27.58%
Income-27.94M PEG- EPS next Q-0.13 Inst Own43.82% Short Float1.38% Perf Quarter32.05%
Sales0.00M P/S- EPS this Y75.60% Inst Trans1.69% Short Ratio1.72 Perf Half Y56.27%
Book/sh2.46 P/B1.84 EPS next Y-36.27% ROA-19.90% Short Interest0.66M Perf Year-24.86%
Cash/sh2.95 P/C1.53 EPS next 5Y- ROE-26.74% 52W Range2.00 - 7.22 Perf YTD-3.29%
Dividend Est.- P/FCF- EPS past 5Y- ROI-17.85% 52W High-37.45% Beta0.16
Dividend TTM- Quick Ratio12.57 Sales past 5Y0.00% Gross Margin- 52W Low125.81% ATR (14)0.32
Dividend Ex-Date- Current Ratio12.57 EPS Y/Y TTM-335.76% Oper. Margin0.00% RSI (14)67.63 Volatility8.61% 8.68%
Employees15 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.33 Target Price19.75
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q87.09% Payout- Rel Volume3.98 Prev Close4.30
Sales Surprise- EPS Surprise-13.41% Sales Q/Q- EarningsAug 13 BMO Avg Volume385.15K Price4.52
SMA2017.38% SMA5021.78% SMA20017.26% Trades Volume1,482,128 Change5.03%
Date Action Analyst Rating Change Price Target Change
Sep-05-24Initiated H.C. Wainwright Neutral $5
May-03-24Initiated Piper Sandler Overweight $26
Oct-10-23Initiated Ladenburg Thalmann Buy $10
Aug-25-23Initiated Oppenheimer Outperform $17
Jun-22-23Initiated Guggenheim Buy $20
Jun-14-23Initiated Chardan Capital Markets Buy $14
May-24-23Initiated Raymond James Strong Buy $20
Sep-03-24 06:00AM
Aug-13-24 09:21AM
Aug-12-24 04:05PM
Aug-09-24 04:05PM
Aug-01-24 08:00AM
06:10AM Loading…
Jul-12-24 06:10AM
06:08AM
Jun-14-24 06:00AM
Jun-06-24 06:00AM
Jun-03-24 06:00AM
May-31-24 09:55AM
May-29-24 06:00AM
May-24-24 06:18AM
May-15-24 09:55AM
May-14-24 12:00PM
03:26PM Loading…
May-12-24 03:26PM
May-10-24 03:14PM
May-09-24 01:56PM
06:00AM
Apr-25-24 02:18AM
Apr-18-24 09:22AM
Apr-08-24 06:00AM
Mar-28-24 11:54AM
06:00AM
Mar-04-24 06:00AM
Feb-02-24 06:00AM
Jan-08-24 06:00AM
Jan-03-24 06:00AM
Dec-04-23 06:00AM
Nov-14-23 06:00AM
06:30AM Loading…
Nov-13-23 06:30AM
Sep-12-23 05:00AM
Sep-05-23 08:55PM
Aug-25-23 09:42AM
Aug-14-23 07:00AM
Jun-23-23 06:30AM
Jun-06-23 06:34AM
04:00AM
Jun-01-23 10:20AM
Apr-27-23 07:39AM
Apr-14-23 05:00AM
Mar-27-23 09:35AM
Mar-21-23 06:13AM
Zura Bio Ltd. is a clinical-stage biotechnology company that engages in the development of novel medicines for immune disorders. It focuses on the development of ZB-168, a treatment for Alopecia Areata and other inflammatory diseases. The company was founded by Someit Sidhu on January 18, 2022 and is headquartered in Henderson, NV.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Thiara ParvinderDirectorSep 11 '24Sale2.703,800,00010,260,0001,001,633Sep 13 04:15 PM
Sidhu SomeitDirectorSep 04 '24Sale3.8751,728200,1872,085,418Sep 06 05:37 PM
Sidhu SomeitDirectorSep 04 '24Proposed Sale3.8552,000200,000Sep 04 12:55 PM
Ploos van Amstel ArnoutDirectorMay 17 '24Buy6.2080,000496,000100,000May 23 08:53 AM
Howell MichaelSee RemarksApr 22 '24Buy3.137,98724,9997,987Apr 24 06:54 PM
Nistala KiranExecutive Vice PresidentApr 22 '24Buy3.133,19510,0003,195Apr 24 06:53 PM
Munshi AmitDirectorApr 22 '24Buy3.13159,744499,999777,384Apr 24 06:52 PM
Sidhu SomeitDirectorApr 22 '24Buy3.131,186,9013,715,0001,186,901Apr 24 06:51 PM
Thiara ParvinderDirectorDec 12 '23Sale4.002,000,0008,000,0004,801,633Dec 14 03:35 PM